• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Pharmacokinetics and systemic availability of the antihypertensive agent indoramin and its metabolite 6-hydroxyindoramin in healthy subjects.

作者信息

Pierce D M, Abrams S M, Franklin R A

机构信息

Drug Metabolism and Pharmacokinetics Section, Wyeth Research (UK) Ltd., Maidenhead, Berks.

出版信息

Eur J Clin Pharmacol. 1987;32(6):619-23. doi: 10.1007/BF02455999.

DOI:10.1007/BF02455999
PMID:3653231
Abstract

We have studied the pharmacokinetics and absolute systemic availability of indoramin (50 mg) given orally in solution or as a tablet with reference to intravenously administered drug (0.15 mg/kg) in 9 healthy volunteers. After intravenous administration the median apparent volume of distribution was 6.3 l X kg-1, plasma clearance was 20.0 ml X min-1 X kg-1, and terminal half-time was 4.1 h. When given by tablet indoramin was absorbed with moderate rapidity, with a median tmax of 1.5 h. The median systemic availability was 24%. After oral administration in solution the drug was more rapidly absorbed, with a median tmax of 1.0 h (p less than 0.01). The median systemic availability was 43% (15-85%). Plasma concentrations of an active metabolite, 6-hydroxyindoramin, after single oral doses in either dosage form, were of a similar order to those of unchanged drug and fell with similar rapidity. After intravenous administration, however, concentrations of the metabolite were negligible.

摘要

相似文献

1
Pharmacokinetics and systemic availability of the antihypertensive agent indoramin and its metabolite 6-hydroxyindoramin in healthy subjects.
Eur J Clin Pharmacol. 1987;32(6):619-23. doi: 10.1007/BF02455999.
2
Intra- and inter-subject variation in the pharmacokinetics of indoramin and its 6-hydroxylated metabolite.
Eur J Clin Pharmacol. 1988;35(2):195-8. doi: 10.1007/BF00609252.
3
Pharmacokinetics of indoramin and its 6-hydroxylated metabolite after repeated oral dosing.
Biopharm Drug Dispos. 1988 Mar-Apr;9(2):147-57. doi: 10.1002/bod.2510090204.
4
The pharmacokinetics of oral indoramin during pregnancy.孕期口服吲哚拉明的药代动力学。
Br J Clin Pharmacol. 1990 Apr;29(4):397-401. doi: 10.1111/j.1365-2125.1990.tb03656.x.
5
Pharmacokinetics of indoramin and its metabolite 6-hydroxyindoramin after single and multiple doses to cirrhotic liver patients.
J Cardiovasc Pharmacol. 1986;8 Suppl 2:S20-4. doi: 10.1097/00005344-198600082-00005.
6
The pharmacokinetics of indoramin and 6-hydroxyindoramin in poor and extensive hydroxylators of debrisoquine.
Eur J Clin Pharmacol. 1987;33(1):59-65. doi: 10.1007/BF00610381.
7
A review of the clinical pharmacokinetics and metabolism of the alpha 1-adrenoceptor antagonist indoramin.
Xenobiotica. 1990 Dec;20(12):1357-67. doi: 10.3109/00498259009046634.
8
Pharmacokinetic interaction between indoramin and ethanol.
Hum Toxicol. 1989 May;8(3):237-41. doi: 10.1177/096032718900800306.
9
Pharmacokinetics of oral indoramin in elderly and middle-aged female volunteers.
Eur J Clin Pharmacol. 1984;27(2):247-9. doi: 10.1007/BF00544054.
10
Recent developments in the pharmacology and pharmacokinetics of indoramin.
J Cardiovasc Pharmacol. 1986;8 Suppl 2:S16-9. doi: 10.1097/00005344-198600082-00004.

引用本文的文献

1
Clinical pharmacokinetics of vasodilators. Part II.血管扩张剂的临床药代动力学。第二部分。
Clin Pharmacokinet. 1998 Jul;35(1):9-36. doi: 10.2165/00003088-199835010-00002.
2
Individual variation in first-pass metabolism.首过代谢的个体差异。
Clin Pharmacokinet. 1993 Oct;25(4):300-28. doi: 10.2165/00003088-199325040-00005.
3
The pharmacokinetics of indoramin and 6-hydroxyindoramin in poor and extensive hydroxylators of debrisoquine.
Eur J Clin Pharmacol. 1987;33(1):59-65. doi: 10.1007/BF00610381.

本文引用的文献

1
Determination of therapeutic concentrations of indoramin by liquid chromatography with fluorimetric detection.
Analyst. 1981 Jun;106(1263):717-9. doi: 10.1039/an9810600717.
2
Pharmacokinetics of oral indoramin.口服吲哚拉明的药代动力学
Curr Med Res Opin. 1982;8(1):51-3. doi: 10.1185/03007998209109757.
3
The pharmacology of verapamil. IV. Kinetic and dynamic effects after single intravenous and oral doses.
Clin Pharmacol Ther. 1982 Apr;31(4):418-26. doi: 10.1038/clpt.1982.54.
4
4
Intra- and inter-subject variation in the pharmacokinetics of indoramin and its 6-hydroxylated metabolite.
Eur J Clin Pharmacol. 1988;35(2):195-8. doi: 10.1007/BF00609252.
5
Metabolites of antihypertensive drugs. An updated review of their clinical pharmacokinetic and therapeutic implications.抗高血压药物的代谢产物。其临床药代动力学及治疗意义的最新综述。
Clin Pharmacokinet. 1991 Nov;21(5):331-43. doi: 10.2165/00003088-199121050-00002.
Studies on the metabolism of the new anti-hypertensive agent, indoramin, in man.新型抗高血压药物吲哚拉明在人体中的代谢研究。
Eur J Clin Pharmacol. 1983;24(5):629-34. doi: 10.1007/BF00542212.
5
Pharmacokinetics of intravenous indoramin in middle-aged male and female volunteers.
Eur J Clin Pharmacol. 1983;25(2):243-6. doi: 10.1007/BF00543798.
6
Pharmacokinetics of oral indoramin in elderly and middle-aged female volunteers.
Eur J Clin Pharmacol. 1984;27(2):247-9. doi: 10.1007/BF00544054.
7
Commentary: a physiological approach to hepatic drug clearance.述评:肝脏药物清除的生理学方法
Clin Pharmacol Ther. 1975 Oct;18(4):377-90. doi: 10.1002/cpt1975184377.
8
Pharmacokinetics of indoramin in man.吲哚拉明在人体中的药代动力学。
Br J Clin Pharmacol. 1976 Jun;3(3):489-95. doi: 10.1111/j.1365-2125.1976.tb00626.x.
9
Prazosin, pharmacokinetics and concentration effect.哌唑嗪、药代动力学及浓度效应。
Eur J Clin Pharmacol. 1979 Sep;16(3):177-81. doi: 10.1007/BF00562058.
10
Labetalol: bioavailability, drug plasma levels, plasma renin and catecholamines in acute and chronic treatment of resistant hypertension.拉贝洛尔:在顽固性高血压急性和慢性治疗中的生物利用度、药物血浆水平、血浆肾素和儿茶酚胺
Aust N Z J Med. 1978 Dec;8(6):602-9. doi: 10.1111/j.1445-5994.1978.tb04847.x.